BMY vs CBRE · P/E 17, rev $24.46B vs P/E 43, rev $21.75B
Bristol-Myers Squibb Company (BMY) versus CBRE Group Inc Class A (CBRE) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported CBRE revenue for 2026-06-30 was $21.75B. Net income was $522.0M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Not investment advice. Open the BMY and CBRE stock pages for the full models.
Not investment advice.